Proton pump inhibitor

CCP: Erosive esophagitis, short term treatment of GERD, Zollinger-Ellison syndrome, peptic ulcer disease

• Hypersensitivity
• Concomitant use with rilpivirine.

Caution

• Long term use
• High dose
• Hypomagnesemia
• Patients 50 years and older.
• Concomitant use with Clopidogrel.

Onset: PO 2.5 hours, IV 15-30 minutes

Duration: 7 days

Peak plasma time: 2.8 hours.

Half-life: 1 hour

• Headache
• Abdominal pain
• Facial edema
• Generalized edma
• Chest pain
• Diarrhea
• Constipation
• Pruritus
• Rash
• Hyperglycemia
• Nausea and vomiting

• PPI’s are possibly associated with increased incidence of CDAD.
• Cutaneous lupus erythematosus and systemic lupus erythematosus reported with PPI’s.
• Caution with severe hepatic impairment.
• PPI’s may be associated with an increased risk of osteoporosis related fractures.
• PPI’s may decrease the effectiveness of Plavix.
• Hypomagnesemia may occur with prolonged use.
• Therapy increases risk of Salmonella, Campylobacter, and other infections.
• Infusion thrombophlebitis
• Acute interstitial nephritis
• Acute tubulointerstitial nephritis
• Increased risk of fundic gland polyps.
• May elevate or prolong serum methotrexate.

• Nelfinavir
• Rilpivirine
• Acalabrutinib
• Atazanavir
• Bosutinib
• Captopril
• Cefditoren pivoxil
• Cefpodoxime proxetil
• Cefuroxime axetil
• Dacomitinib
• Dasatinib
• Dextroamphetamine
• Erlotinib
• Ferrous gluconate
• Ferrous sulfate
• Fosinipril
• Gefitinib
• Ketoconazole
• Levothyroxine
• Mefenamic acid
• Mesalamine
• Methylphenidate
• Neratinib
• Nilotinib
• Pazopanib
• Pexidartinib
• Posaconazole
• Selpercatinib
• Triazolam
• Velpatasvir